NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Introduction: This study is a European multicentre, randomised, double-blind, placebo-controlled trial investigating the efficacy and safety of nilvadipine as a disease course modifying treatment for mild-to-moderate Alzheimer's disease (AD) in a phase III study that will run for a period of 82 weeks with a treatment period of 78 weeks. Methods and analysis: Adult patients, males and females over 50 years with mild-to-moderate AD as defined by the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's disease and Related Disorders Association (NINCDS-ADRDA) criteria, will be included in the study. It aims to recruit a total of 500 patients with AD; 250 in the nilvadipine group and 250 in the placebo group. Participants will be randomised to receive nilvadipine, an 8 mg overencapsulated, sustained release capsule, or a matching overencapsulated placebo (sugar pill) for a period of 78 weeks of treatment. The primary efficacy outcome measure in this study is the change in cognitive function as assessed by the Alzheimer's disease Assessment Scale (ADAS-Cog 12) from baseline to the end of treatment duration (78 weeks). There are two key secondary outcome measures, the Clinical Dementia Rating Scale Sum of Boxes (CDR-sb) and the Disability Assessment for Dementia (DAD). If a statistically significant effect is seen in the primary outcome, CDR-sb will be considered to be a coprimary end point and only the DAD will contribute to the secondary outcome analysis. Ethics and dissemination: The study and all subsequent amendments have received ethical approval within each participating country according to national regulations. Each participant will provide written consent to participate in the study. All participants will remain anonymised throughout and the results of the study will be published in an international peer-reviewed journal. Trial registration number: EUDRACT Reference Number: 2012-002764-27.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Forette, F., Seux, M.-L., Staessen, J. A., Thijs, L., Birkenhäger, W. H., Babarskiene, M.-R., Babeanu, S., Bossini, A., Gil-Extremera, B., Girerd, X., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03086-4 · Cited by 1,441
Forette, F. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.18.2046 · Cited by 898
Absence of bleeding on probing An indicator of periodontal stability
Lang, N. P., Adler, R., Joss, A., & Nyman, S. (1990) · Journal of Clinical Periodontology · doi:10.1111/j.1600-051x.1990.tb01059.x · Cited by 671 · cited 3×
“At all subsequent visits, the following assessments will be carried out: (1) concomitant medications check; (2) adverse events check; (3) BP measurements (sitting and standing) and (4) medication compliance check.”
Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging
Yasar, S., Corrada, M., Brookmeyer, R., & Kawas, C. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.03.009 · Cited by 116
Paris, D., Bachmeier, C., Patel, N., Quadros, A., Volmar, C.-H., Laporte, V., Ganey, J., Beaulieu-Abdelahad, D., Ait-Ghezala, G., Crawford, F., et al. (2011) · Molecular Medicine · doi:10.2119/molmed.2010.00180 · Cited by 114
Self-citation
Cited by
Amyloid Beta: Structure, Biology and Structure-Based Therapeutic Development
Chen, G.-F., Xu, T.-H., Yan, Y., Zhou, Y.-R., Jiang, Y., Melcher, K., & Xu, H. E. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.28 · Cited by 1,965
Therapeutic strategies for Alzheimer's disease in clinical trials
Godyń, J., Jończyk, J., Panek, D., & Malawska, B. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2015.07.006 · Cited by 452
Drug candidates in clinical trials for Alzheimer’s disease
Hung, S.-Y., & Fu, W.-M. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0355-7 · Cited by 420
Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial
Lawlor, B., Segurado, R., Kennelly, S., Olde Rikkert, M. G. M., Howard, R., Pasquier, F., Börjesson-Hanson, A., Tsolaki, M., Lucca, U., Molloy, D. W., et al. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002660 · Cited by 193
Self-citationBlood Pressure Variability and Progression of Clinical Alzheimer Disease
de Heus, R. A. A., Olde Rikkert, M. G. M., Tully, P. J., Lawlor, B. A., Claassen, J. A. H. R., & for the NILVAD Study Group (2019) · Hypertension · doi:10.1161/hypertensionaha.119.13664 · Cited by 88
Self-citation
Metadata
- Authors
- Lawlor, B., Kennelly, S., O'Dwyer, S., Cregg, F., Walsh, C., Coen, R., Kenny, R. A., Howard, R., Murphy, C., Adams, J., Daly, L., Segurado, R., Gaynor, S., Crawford, F., Mullan, M., Lucca, U., Banzi, R., Pasquier, F., Breuilh, L., Riepe, M., Kalman, J., Wallin, A., Borjesson, A., Molloy, W., Tsolaki, M., & Olde Rikkert, M.
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2014-10
- Volume
- 4
- Issue
- 10
- Pages
- e006364
- ISSN
- 2044-6055 (ISSN-L)
- OpenAlex
- W2065301205
- Cited by
- 45
- References
- 6
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease. https://app.cochat.ai/papers/10.1136/bmjopen-2014-006364
- The paper
- Lawlor, B., Kennelly, S., O'Dwyer, S., Cregg, F., Walsh, C., Coen, R., Kenny, R. A., Howard, R., Murphy, C., Adams, J., Daly, L., Segurado, R., Gaynor, S., Crawford, F., Mullan, M., Lucca, U., Banzi, R., Pasquier, F., Breuilh, L., . . . Olde Rikkert, M. (2014). NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease. BMJ Open. https://doi.org/10.1136/bmjopen-2014-006364
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.